Lymphomatoid drug reaction to ustekinumab

Archives of Dermatology

Volumn 147, Issue 8, 2011, Pages 992-993

  Jung, Jae ^a   Levin, Ethan Charles ^a   Jarrett, Robert ^a   Lu, Dongsi ^a   Mann, Caroline ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE; STEROID; USTEKINUMAB;

ADULT; CASE REPORT; CD3+ T LYMPHOCYTE; CD30+ T LYMPHOCYTE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LETTER; PRIORITY JOURNAL; PSEUDOLYMPHOMA; PSORIASIS; REMISSION; RESPIRATORY TRACT DISEASE; SKIN BIOPSY; T LYMPHOCYTE; TREATMENT WITHDRAWAL;

ADULT; ANTIBODIES, MONOCLONAL; DRUG ERUPTIONS; FEMALE; HUMANS; LYMPHOMA; PSORIASIS;

EID: 80051674395     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.213     Document Type: Letter

References (5)

1. Elder JT, Bruce AT, Gudjonsson JE, et al. Molecular dissection of psoriasis: integrating genetics AND biology. J Invest Dermatol. 2010;130(5):1213-1226.
2. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther. 2010;10(4):587-604.
3. Elliott M, Benson J, Blank M, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci. 2009;1182:97-110.
4. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280(5368):1435-1438. (Pubitemid 28264837)
5. Fieschi C, Casanova JL. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol. 2003;33(6):1461-1464. (Pubitemid 36790405)